Malarone (Proguanil Hydrochloride, Atovaquone)

The combination works by targeting two essential parasite pathways. Atovaquone blocks the mitochondrial electron transport chain, halting ATP production, while proguanil is converted to cycloguanil, which inhibits dihydrofolate reductase, preventing DNA synthesis. Together they synergistically stop parasite replication.

The specific dose of Malarone is determined by the prescribing clinician based on the indication, patient weight, age, and renal or hepatic function. Healthcare providers follow approved guidelines to select the appropriate tablet strength and dosing schedule for each individual.

Malarone is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are limited human data. It may be used during pregnancy only when the potential benefit justifies the risk. Caution is advised during breastfeeding because the drug can be excreted in milk.

To order Malarone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details and any required import documentation.

Compared with older agents such as chloroquine, Malarone offers a broader spectrum against chloroquine‑resistant Plasmodium strains and has a convenient once‑daily dosing regimen. Its safety profile is generally favorable, though drug‑interaction potential is higher than some alternatives, requiring careful review of concomitant medications.

Malarone tablets should be stored at ambient temperature below 25 °C, in their original blister pack, and protected from moisture and direct sunlight. Keep the medication out of reach of children and do not use if the packaging is damaged.

Malarone is taken orally with a full glass of water, preferably with food or a milky drink to improve absorption. Tablets are swallowed whole and should be taken at the same time each day according to the prescriber’s schedule.

Serious adverse events, although rare, include severe skin reactions such as Stevens‑Johnson syndrome, significant liver injury manifested by elevated transaminases, and hematologic problems like neutropenia or anemia. Patients should seek immediate medical attention if they develop rash, jaundice, or unexplained bruising.

Malarone is contraindicated in individuals with known hypersensitivity to atovaquone, proguanil, or any tablet components. Patients with severe renal or hepatic impairment should avoid use unless specifically advised by a physician, and those with G6PD deficiency should be monitored closely for hemolytic events.